- Home
- Equipment
- asia middle east
- cardiovascular risk
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Cardiovascular Risk Equipment Supplied In Asia Middle East
4 equipment items found
Manufactured by:Itamar Medical Ltd. based inAtlanta, GEORGIA
What if you could identify high risk patients at the earliest stage of their cardiovascular disease - would you treat them differently? The EndoPAT – the only FDA-cleared test for the non-invasive assessment of Endothelial Dysfunction (arterial health); clinically proven by leading cardiologists through prestigious peer-reviewed studies as a valuable tool ...
Manufactured by:Omron Healthcare, Inc based inHoofddorp, NETHERLANDS
OMRON VIVA is a medical device with clinically validated accuracy of key parameters that allow you to better understand your heart's health (visceral fat, fat and skeletal muscle) and are proven to be predictive for cardiovascular ...
Manufactured by:Arkray USA, Inc. based inMinneapolis, MINNESOTA (USA)
Highly Accurate1 Blood Glucose Testing in a Feature-focused System. Tight glycemic control can reduce the risk of diabetes-related complications by at least 42%*.2. * 76% reduced risk of eye disease; 50% reduced risk of kidney disease; 60% reduced risk of nerve disease; 57% reduced risk of nonfatal heart attack, ...
Manufactured by:DxGen Corp. based inGunpo-si, SOUTH KOREA
Test Kit is for in-vitro diagnostic (IVD) use to determine Glycated Albumin (GA) and Albumin quantitatively from serum or plasma. It is useful at initial assessment, the onset of therapy, and post-therapeutic monitoring of glycemic control. ...